New Study Exposes Harmful Effects of IRA’s ‘Pill Penalty’ on Small Molecule Drugs A recently published peer-reviewed study is shedding light on the unintended yet far-reaching consequences of the Inflation Reduction Act (IRA) on the U.S. biopharmaceutical sector—particularly in the…
Exicure Approaches Phase 2 Completion for GPC-100 in Multiple Myeloma Treatment Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company advancing novel small molecule therapeutics for immuno-oncology and hematological malignancies, announced a significant milestone today in its ongoing Phase 2 clinical…
Exicure Announces Plans for New Clinical Trial in Acute Myeloid Leukemia (AML) Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company focused on developing innovative therapeutics targeting diseases with high unmet medical needs, announced significant updates today regarding its lead investigational…
Biologic Therapy Boosts Pregnancy Outcomes in High-Risk APS Patients Landmark Clinical Trial Finds Certolizumab Significantly Improves Pregnancy Outcomes in Women with Antiphospholipid Syndrome In a groundbreaking advancement for maternal-fetal medicine and autoimmune disease treatment, a phase 2 clinical trial co-led…
Two Major Trials Identify Effective Antibiotic Selection Method for Hospitalized Infection Patients In a significant advancement for infectious disease care and antibiotic stewardship, two large-scale clinical trials funded by the National Institutes of Health (NIH) have demonstrated that integrating real-time,…
Amylyx Begins Dosing in Phase 1 LUMINA Trial of AMX0114 for ALS Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a biopharmaceutical company dedicated to the development of innovative treatments for neurodegenerative diseases, has announced a significant milestone in its mission to combat…
NexThera Begins U.S. Trial with First Patient Dosed for Wet AMD Eye Drop NT-101 NexThera Co., Ltd., a biotechnology company at the forefront of ophthalmic innovation, announced a pivotal milestone in its drug development journey: the initiation of a Phase…
LifeMine Doses First Participant in Phase 1 Trial of Novel Immunosuppressive LIFE-001 LifeMine Therapeutics Inc., a clinical-stage biopharmaceutical company redefining small molecule discovery through its proprietary genomic search platform, has officially dosed the first participant in a Phase 1 clinical…
City of Hope Unveils Promising New Targeted Approach for Pancreatic Cancer In a significant stride forward in the battle against one of the most lethal forms of cancer, scientists at City of Hope®—a leading U.S. cancer research and treatment center—have…
Agitated Solutions Gets FDA IND Nod for Phase 3 Contrast Agent Trial Agitated Solutions, Incorporated (ASI), a medical technology company focused on cardiovascular imaging innovation, announced a pivotal regulatory milestone this week: the U.S. Food and Drug Administration (FDA) has…
Corcept Begins Trial of Relacorilant Combo in Resistant Ovarian Cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage biopharmaceutical company focused on the discovery and development of innovative therapies that modulate the effects of the stress hormone cortisol to treat serious…
Verge Genomics Identifies Digital Biomarkers for Early ALS Progression in VRG50635 Trial Verge Genomics, a trailblazer in AI-powered drug discovery and development, today announced pivotal findings that could reshape the design and execution of clinical trials for neurodegenerative diseases. In…